Vanguard Group
APGE icon

Vanguard Group’s Apogee Therapeutics APGE Stock Holding History

Vanguard Group’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$216M Buy
2,857,824
+612,193
+27% +$38.6M ﹤0.01% 1513
2025
Q3 		$89.2M Buy
2,245,631
+136,693
+6% +$5.22M ﹤0.01% 1909
2025
Q2 		$91.6M Buy
2,108,938
+26,332
+1% +$1M ﹤0.01% 1864
2025
Q1 		$77.8M Sell
2,082,606
-14,991
-0.7% -$580K ﹤0.01% 1899
2024
Q4 		$95M Sell
2,097,597
-29,445
-1% -$1.5M ﹤0.01% 1897
2024
Q3 		$125M Buy
2,127,042
+156,722
+8% +$7.51M ﹤0.01% 1769
2024
Q2 		$77.5M Buy
1,970,320
+101,654
+5% +$4.93M ﹤0.01% 1956
2024
Q1 		$124M Buy
1,868,666
+705,795
+61% +$30.8M ﹤0.01% 1756
2023
Q4 		$32.5M Buy
1,162,871
+41,107
+4% +$824K ﹤0.01% 2370
2023
Q3 		$23.9M Buy
+1,121,764
New +$24.7M ﹤0.01% 2481

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Group's APGE Position: Q4 2025 in Review

Vanguard Group increased its Apogee Therapeutics (APGE) stake by 27% in Q4 2025, buying an estimated $38.6M and bringing the position to 2,857,824 shares worth $216M. The position accounts for ﹤0.01% of the portfolio, ranked #1513.

Vanguard Group first reported a position in APGE in Q3 2023 and has held it in 10 quarters since. 206 funds tracked by Wall St. Rank hold APGE as of Q4 2025.

  • Vanguard Group held 2,857,824 shares of Apogee Therapeutics worth $216M as of Q4 2025.
  • Vanguard Group bought 612,193 Apogee Therapeutics shares in Q4 2025, an estimated $38.6M.
  • Apogee Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1513 holding.
  • Vanguard Group first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 10 quarters since.
  • 206 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.